Evidence map›Paper›PMID 22278291›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2012

Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.

C S Matos, A de Souza Andrade, N S Oliveira, T F Barros

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. The status of cryptococcosis in Latin America.Memorias do Instituto Oswaldo Cruz · 2018
    Review
  10. Ecoepidemiology of Cryptococcus gattii in Developing Countries.Journal of fungi (Basel, Switzerland) · 2017
    Review
  11. Candida glabrata Biofilms: How Far Have We Come?Journal of fungi (Basel, Switzerland) · 2017
    Review
  12. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016
    Article
  13. Cryptococcus gattii infections.Clinical microbiology reviews · 2014
    Review
  14. Article
  15. Article
  16. Review
  17. Cryptococcus gattii, no longer an accidental pathogen?Current fungal infection reports · 2012
    Article
  18. Article
  19. Molecular types of Cryptococcus species isolated from patients with cryptococcal meningitis in a Brazilian tertiary care hospital.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

C S MatosGraduate Program in Pharmacy, Faculty of Pharmacy, UFBA, Salvador, Brazil.
A de Souza Andrade
N S Oliveira
T F Barros
Hospital São Rafael · BRUniversidade Federal da Bahia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine the profiles of susceptibility to antifungal and the genotypes of clinical isolates of Cryptococcus in Bahia, Brazil, 62 isolates were collected from cases of meningitis in the period from 2006 to 2010. Their susceptibilities to fluconazole, itraconazole, amphotericin B and 5-flucytosine were determined by the broth microdilution technique described by the Clinical and Laboratory Standards Institute and genotyping of the URA5 gene was accomplished by restriction fragment length polymorphism. C. neoformans accounted for 79% of the identified yeast and C. gattii represented the remaining 21%. Evaluation of the genotypes determined that 100% of the C. gattii isolates belong to the VGII genotype, and 98% of the C. neoformans isolates belong to the VNI genotype. Determination of susceptibility revealed isolates resistant to fluconazole (4.8%), 5-flucytosine (1.6%) and amphotericin B (3.2%); the stratification of sensitivity results for each species showed significant differences in susceptibility to azoles. This study is the first to describe the susceptibility profiles of molecular and clinical isolates of Cryptococcus in Bahia, Brazil. The high percentage of C. gattii isolates belonging to the VGII genotype and its lower susceptibility to antifungal agents highlight the importance of knowing which species are involved in cryptococcal infections in northeastern Brazil.

Indexed as

Molecular TypingMycological Typing TechniquesAntifungal AgentsBrazilCryptococcosisCryptococcus gattiiCryptococcus neoformansDNA, FungalFungal ProteinsGenotypeHumansMicrobial Sensitivity TestsPolymorphism, Restriction Fragment LengthAntifungal AgentsDNA, FungalFungal Proteins

Identifiers

PMID22278291
PMCPMC3364408
OpenAlexW2050020487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.